A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?

Johann Tang, Scott Williams, Keen-Hun Tai, Joanne Dean, Gillian Duchesne

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


We analyzed data from 88 patients with T1aa??T3a, N0, M0 prostate adenocarcinoma treated on a prospective Phase I/II HDRB boost protocol of 16 or 20 Gy in four fractions, without planned androgen deprivation therapy.
Original languageEnglish
Pages (from-to)256 - 261
Number of pages6
Publication statusPublished - 2006

Cite this